Venom of
Platelet aggregation plays a vital role in hemostasis by maintaining the integrity of blood vessel walls (1) (2) (3) , in facilitating the activation of coagulant factors (4 -6) , and in clot retraction (7, 8) . Thus an aberration in platelet aggregation can cause havoc as seen in myocardial infarction and stroke wherein small clots formed in the blood vessels restrict the supply to the heart and brain. Hence, antiplatelet agents are sought after, as they would be useful in the prevention/treatment of atherosclerosis and cardiovascular and cerebrovascular diseases.
Several snake venom proteins interfere in thrombosis and hemostasis. Some of these proteins affect platelet aggregation and/or blood coagulation. A number of snake venom proteins that inhibit platelet aggregation have been purified and characterized (for reviews, see 9, 10) . This heterogeneous group of proteins and polypeptides contains enzymes such as nucleotidases, L-amino acid oxidase, proteinases, and phospholipase A 2 as well as nonenzymatic proteins. They inhibit platelet aggregation by different mechanisms and hence provide useful and novel tools for the study of molecular mechanisms in platelet aggregation. In some instances they have also helped in developing new antiplatelet agents. For example, disintegrins, a group of potent nonenzymatic inhibitors from viperid and crotalid venoms (11, 12) , have helped in the design of prototypes of new antiplatelet agents (13) .
Australian snake venoms are among the most lethal in the world, containing interesting and distinctly different toxins, most probably because of different evolutionary pressures. Several venoms of Australian snakes are known to interfere with platelet aggregation as well as blood coagulation (14, 15) . Recently, an inhibitor of platelet aggregation from Austrelaps su-perba (16, 17) venom was purified and characterized. The inhibitor is a PLA 2 2 enzyme with molecular weight of 15,000. The inhibiton by A. superba inhibitor is dependent on PLA 2 enzyme activity of the protein (16, 17) . The mechanism of this inhibitor is not yet clear.
Acanthophis antarcticus contains numerous postsynaptic neurotoxins such as acanthophin a (18) , and A. antarcticus toxins Aa b and Aa c (19, 20) and Aa e1 and e2 (21) . This family of neurotoxins has been well studied and characterized. Recently, two isoforms of PLA 2 were also purified from this venom and were named acanthoxins (22) . In this paper, we report the purification and partial characterization of two inhibitors of platelet aggregation from A. antarcticus venom. These inihibitors are PLA 2 enzymes and were named acanthin I and II. Acanthins are among the most potent antiplatelet inhibitors isolated thus far from snake venom.
MATERIALS AND METHODS
Materials. Lyophilized A. antarcticus venom was obtained from Venom Supplies (Tanunda, SA, Australia). Bio-Gel P-2, Bio-Gel P-30, UNO-S1 (7 ϫ 35 mm), and cartridge and reagents for pI determination were purchased from Bio-Rad (Hercules, CA). C 5 column (Jupiter 5, 4.6 ϫ 250 mm) was from Phenomenex (Torrance, CA). Reagents for N-terminal sequencing and amino acid analysis were from Applied Biosystem (Foster City, CA) and Shimadzu (Kyoto, Japan), respectively. Collagen and ADP for platelet aggregation assay was purchased from Chrono-Log (Havertown, PA). Lecithin used as a substrate in phospholipase assay was obtained from ICN Biochemicals (Aurora, OH). The chromatographic reagents acetonitrile and TFA were from Fisher Scientific (Fair Lawn, NJ) and Fluka (Buchs, Switzerland), respectively. All other chemicals used were of analytical grade purchased from Sigma (St. Louis, MO).
Isolation and purification of antiplatelet proteins. Lyophilized crude venom (150 mg) was dissolved in 1.0 ml of distilled water and applied onto a Bio-Gel P-30 column (1.5 ϫ 120 cm) equilibrated with 50 mM ammonium acetate, pH 5.0. Proteins were eluted with the same buffer at a flow rate of 18 ml/h and elution profile was monitored at 280 nm. Fractions that showed potent antiplatelet activity were pooled and purified further on UNO-S1, a cation-exchange column which was equilibrated with 50 mM ammonium acetate, pH 5.0. The bound proteins were eluted with a linear gradient of sodium chloride at a flow rate of 1.0 ml/min. Active fractions from UNO-S column were then subjected separately to further purification on Jupiter C 5 reversed-phase column. The column was equilibrated with 0.1% TFA and the bound proteins were eluted with a linear gradient of acetonitrile in 0.1% TFA at a flow rate of 1.0 ml/min and the eluant was monitored at 280 nm. The purified proteins were named acanthin I and II.
Electrospray mass spectrometry. Samples were dissolved in 50% acetonitrile and 50% water and analyzed using Perkin-Elmer Sciex API 300 triple quadrupole instrument equipped with an ionspray interface. The ionspray voltage was set at 4600 V and the orifice voltage at 30 V. Nitrogen was used as a curtain gas with a flow rate of 0.6 L/min while compressed air was utilized as a nebulizer gas. The samples were infused into the mass spectrometer at a flow rate of 5 l/min. Capillary zone electrophoresis. Capillary zone electrophoresis was performed on a BioFocus 3000 Capillary Electrophoresis System from Bio-Rad. The samples were injected under pressure mode of 10 psi/s into a coated capillary (25 m ϫ 24 cm). The run was carried out from ϩ to Ϫ polarity mode in 0.1 M phosphate buffer (pH 2.5) at 15°C and at a constant potential of 12 kV. The proteins were detected by UV absorbance of 200 nm.
Isoelectric point determination. The isoelectric point (pI) for acanthin was performed in the same instrument used in capillary zone electrophoresis. The experiment was conducted under the following conditions: The samples were pressure injected at 100 psi for 60 s into a coated capillary (25 m ϫ 24 cm) which was thermally controlled at 27°C. The run was carried out from ϩ to Ϫ polarity mode with focusing and mobilizing voltages at 10 kV. The protein peaks were detected at 280 nm. To determine the pI of acanthin, BioMark synthetic pI markers (pI range Reduction and pyridylethylation. PE acanthins were prepared by resuspending the samples in 100 l of the denaturant buffer (6.0 M guanidinium hydrochloride, 0.13 M Tris, 1 mM EDTA, pH 8.0) containing 0.07 M ␤-mercaptoethanol. The solutions were heated at 37°C for 2 h. Subsequently, 1.5-fold molar excess (over sulfhydryl groups) of 4-vinylpyridine was added and incubated at room temperature. After 2 h, samples were desalted on Bio-Gel P-2 equilibrated with 9% formic acid.
Protein digestion. Digestion of PE acanthins with endoproteinase Lys-C was performed in 100 mM Tris-HCl, pH 8.5, in a molar ratio of 100:1 (substrate:protease) at 37°C for 18 h. PE acanthin II was also treated with 4 mg/ml BNPS-skatole in 70% acetic acid and the reaction carried out for 24 h at 37°C. The digests were fractionated on reversed-phase chromatography on Sephacil C 8 column.
Amino-terminal sequencing. Amino-terminal sequencing was carried out on PE acanthins and their peptides by an automated Edman degradation using an Applied Biosystems 494 pulsed-liquidphase sequencer. Phenylthiohydantoin amino acids were identified using on-line reversed-phase high-performance liquid chromatography on a PTH-C18 column, in an Applied Biosystem 140C analyzer.
Assay for phospholipase activity. Phospholipase A 2 activity was determined by following the protocol of Kawauchi et al. (24) with slight modification. An aqueous emulsion of 20 mM phosphatidylcholine, in the presence of 10 mM Triton X-100 and 10 mM Ca 2ϩ , was used as a substrate. Released fatty acids were titrated at pH 8.0 with NaOH at room temperature with a 718 STAT Titrino pH-stat (Metrohm, Switzerland). The phospholipase activity was expressed as micromoles of phosphatidylcholine hydrolyzed per minute per milligram of enzyme.
Assay for antiplatelet effects. Whole blood was taken from healthy volunteers who had not ingested any medication for 2 weeks. Freshly aspirated blood was collected in 3.8% trisodium citrate (9:1) and used within 3 h. Inhibition of platelet aggregation was determined by electrical impedance in a whole-blood aggregometer (Chrono-Log, Model 500-CA) according to the method of Cardinal and Flower (25) . To an equal volume of phosphate-buffered saline and blood (1 ml total), acanthin was added and incubated at 37°C for 2 min with continual stirring at 1000 rpm. After 2 min platelet aggregation was induced by the addition of either 2 l of collagen (2 g/ml final concentration) or 5 l of ADP (5 M final concentration) and the aggregation was monitored for 5 min. Inhibition of platelet aggregation was calculated as the percentage difference in the rate of platelet aggregation in the presence or the absence of PLA 2 .
RESULTS

Isolation and Purification of Acanthins
Acanthins were purified from crude A. antarcticus venom by a three-step purification process. Initial separation of the venom on gel filtration on Bio-Gel P-30 yielded five major peaks of which only AA2 (Fig.  1A) contained antiplatelet proteins as determined by platelet aggregation assay. Subsequently, AA2 was subjected to a second purification step on UNO-S1, a cation exchanger, resulting in two fractions, namely, AA2I and AA2II (Fig. 1B) . The fractions were then applied separately onto a reversed-phase column, Jupiter C 5 . AA2I eluted as a sharp peak separating away from minor contaminants at 62% acetonitrile while AA2II eluted at 48% acetonitrile (Figs. 1C and  1D ) and these fractions were named acanthin I and II, respectively. Approximate yields of acanthin I and II from 100 mg of venom were 0.39 and 5.07 mg, respectively.
Characterization of Acanthins
Both capillary electrophoresis and electrospray mass spectrometry ( Figs. 2A and 2B) showed that acanthins purified in this manner were homogeneous. All subsequent experiments on biochemical and pharmacological characterization were performed using only purified acanthin I and II. Their physical characteristics are summarized in Table I .
Inhibition of Platelet Aggregation by Acanthins
The antiplatelet effects of acanthins were studied by platelet aggregation assay using healthy human whole blood with either collagen or ADP as platelet agonists. The effects on platelet aggregation appear to be dose dependent with half-maximal (IC 50 ) values of 7 nM for acanthin I and 4 nM for acanthin II when collagen was Cation-exchange chromatography of AA2 on UNO-S1 column. The fraction AA2 separated on Bio-Gel-P 30 was loaded onto UNO-S1 equilibrated with 50 mM ammonium acetate, pH 5.0, and eluted with a linear NaCl gradient (50 mM ammonium acetate, 1.0 M NaCl, pH 5.0) at a flow rate of 1.0 ml/min. (C and D) Reversed-phase chromatography of AA2I and AA2II on Jupiter C 5 column. The column was equilibrated with 0.1% TFA and eluted with acetonitrile gradient in 0.1% TFA at flow rate of 1.0 ml/min. The proteins contained in the peaks were named acanthin I and II.
FIG. 2.
Electrospray mass spectrometry of acanthins. The spectra of (A) acanthin I and (B) acanthin II show a series of mutiple-charged ions, related to molecules bearing six to nine protons. The respective insets depict the purity of acanthin I and acanthin II as determined by capillary zone electrophoresis.
used as an agonist. With ADP as the aggregation inducer, the IC 50 values were 10 and 12 nM for acanthin I and II, respectively (Fig. 3) .
Amino Acid Composition and N-Terminal Sequence of Acanthins
Acanthins were subjected to amino acid sequencing to confirm their identities. Prior to sequence analysis, the proteins were reduced and pyridylethylated. By automated Edman degradation, the first 48 residues of acanthin II were identified unequivocally with a repetitive yield of 93%. The remaining sequence was determined by treatment with BNPS-skatole, which cleaves at the C-terminal side of tryptophan residues generating peptide fragments, W32-69 and W70-118. For overlapping peptides, acanthin II was digested with endoproteinase Lys-C with K64-81 providing the overlap between W32-69 and W70-118. The molecular weights of the peptides were identified by mass spectra analysis and their values matched the calculated masses deduced from the sequences of the respective peptides ( Table II) . The complete sequence of acanthin II is shown in Fig. 4A and its molecular weight corresponds with the value obtained from mass spectra analysis. Similarly with acanthin I, the first 58 residues were determined with a repetitive yield of 92% while the remaining sequence was determined by digesting acanthin I with endoproteinase Lys-C, generating peptide fragments as tabulated in Table III . By homology with acanthin II, the complete sequence of acanthin I was determined (Fig. 4B) .
Acanthin I and II are 119-and 118-amino-acid proteins, respectively, with no posttranslational modification as the amino acid compositions (Table IV) correspond to the molecular weight of the proteins. Acanthin I composition reflects a 42% hydrophobic residue content while neutral and hydrophilic residues accounted for 31 and 27%, respectively. Acanthin II is a   FIG. 3 . Effects of acanthin I and II on platelet aggregation. Different concentrations of acanthin I (q,f) and acanthin II (⅜,Ⅺ) were added to citrated blood and the effects on platelet aggregation were determined by electrical impedance in a whole-blood aggregometer using either collagen (q,⅜) or ADP (f,Ⅺ) as platelet agonist. less hydrophobic protein with a hydrophobic content of 41% while neutral and hydrophilic residues accounted for 31 and 28%, respectively.
DISCUSSION
Several platelet aggregation inhibitors have been purified and characterized from various snake venoms. They include enzymes, such as PLA 2 enzymes, nucleotidases, and fibrinogenases, and nonenzymatic polypeptides, such as disintegrins and mambin. Among these proteins disintegrins isolated from crotalid and viperid snake venoms are some of the most potent inhibitors of platelet aggregation with IC 50 values in the range between 1.2 ϫ 10 Ϫ8 and 2.5 ϫ 10 Ϫ8 M (12, 26) . Disintegrins, as well as mambin, contain Arg-GlyAsp tripeptide sequence in their structures and thus inhibit platelet aggregation by interfering in the interaction between fibrinogen and its receptor, glycoprotein IIb-IIIa complex (for references, see 27).
In our laboratories, several Australian snake venoms were initially screened for their antiplatelet effects. Among these the crude venom from A. antarcticus was found to be one of the most potent inhibitors of platelet aggregation. Thus, we initiated studies to identify the component(s) responsible for the antiplatelet effects of A. antarcticus venom. We have purified two proteins, acanthin I and II, using a three-step sequential purification process which included gel-filtration, cation-exchange, and reversed-phase chromatography. Both these components have similar molec- ular weights of 12,844.58 and 12,895.63, respectively. These molecular weights are similar to monomeric molecular weights of venom PLA 2 enzymes. As expected, acanthin I and II exhibited significant PLA 2 activity when assessed for phospholipase activity by titrimetric method using phosphatidylcholine as a substrate. Their specific activities, 51.57 and 46.85 mol/min/mg, respectively, are similar to those of pseudexin A (43 eq/min/mg), B (53 eq/min/mg) and C (43 eq/min/ mg) (28) . In addition, both are basic proteins with pI values of 10.2 and 10.4, respectively. However, these values differ from the pI value of acanthoxin, a PLA 2 purified from A. antarcticus venom (22) . This could be due to differences in the methods used.
Both acanthins inhibited platelet aggregation in human whole blood. Dose-response studies indicate that acanthin I and II are among the most potent antiplatelet inhibitors known thus far, with IC 50 values of 7 and 4 nM, respectively, with collagen as an agonist. With ADP, a slighter higher concentration was required, giving IC 50 values of 10 nM for acanthin I and 12 nM for acanthin II. As mentioned earlier, several other PLA 2 enzymes also inhibit platelet aggregation and platelet release reactions. However, these inhibit platelet aggregation only at higher concentrations than acanthins. For instance, IC 50 values for inhibition of platelet aggregation by PLA 2 enzymes from A. superba, Agkistrodon halys, and Ophiophagus hannah venoms are 333, 785, and 340 nM, respectively (16, 29, 30) . Thus acanthins appear to be comparatively more potent inhibitors of platelet aggregation than other PLA 2 enzymes.
As a first step toward understanding structure-function relationships of acanthins, we determined the complete amino acid sequence of these proteins. Amino acid and sequence analysis showed that acanthin I and II are 119-and 118-amino-acid proteins, respectively, with no posttranslational modification and are highly homologous (93%). In addition, acanthin I and II have the highest homology of 74 and 77%, respectively, with pseudexin A, a neurotoxic PLA 2 from red-bellied black snake venom (28) . Amino acid sequences and the location of 14 half-cystine residues were typical of elapid and pancreatic phospholipases and hence acanthins can be classified as group I PLA 2 enzymes (31). In addition, amino acid residues that are implicated in enzymatic activity were highly conserved in both isoforms of acanthin. These include the Ca 2ϩ binding site (Y28, G30, G32, D49) (32) (33) (34) and the active site residues (H48, D49, D92, Y52, Y67) (35) (36) (37) (38) . It is interesting to note that both acanthins do not contain Arg-GlyAsp tripeptide sequence. Therefore it is logical to conclude that acanthins may not interfere in the interaction between fibrinogen and its receptor, glycoprotein IIb-IIIa complex, unlike disintegrins and mambin. Disintegrins and mambin are the only other venom polypeptides which inhibit platelet aggregation with inhibitory potencies similar to that of acanthins. Thus the mechanism of inhibition appears to be different from that of Arg-Gly-Asp-containing polypeptides.
Several PLA 2 enzymes interfere in platelet aggregation by specific mechanisms and they can be classified into three major classes (40) . Class A contains PLA 2 s that induce platelet aggregation while in class B they cause inhibition in platelet aggregation and in class C PLA 2 s act as both inducer and inhibitor. Since both isoforms of acanthin inhibit platelet aggregation, they belong to class B. Class B can be further subdivided into two subgroups. In the first subgroup, the PLA 2 enzyme activity is involved in platelet inhibition as was observed with PLA 2 from A. superba (16, 17) and Lachesis muta (41) venoms. In these cases the antiplatelet effects were due to the hydrolysis of phospholipids from the plasma and/or from liproproteins and the formation of lysophosphatidylcholine (17, 41) . Lysophosphatidylcholine dose-dependently inhibits binding of fibrinogen to its glycoprotein IIb-IIIa complex and hence the inhibition of platelet aggregation (17) . However, the second group inhibits platelet aggregation by mechanisms that are independent of its enzyme activity, such as PLA 2 from A. halys venom (29) . These nonenzymatic mechanisms have not yet been deciphered. We are currently examining the role of PLA 2 activity of acanthins in the inhibition of platelet aggregation. Further studies are also under way to determine the structure-function relationships and mechanisms of these potent inhibitors of platelet aggregation.
